

## Press Release

19 June 2025 – 13.30

---

### Cessatech strengthens Executive Management with the promotion of Martin Juhl

- **Welcome to new member of the Executive Management team, Martin Juhl**
- **Acknowledgment of his great contribution and importance for the future development of Cessatech**

On 19 June – Cessatech A/S (“Cessatech” or “the Company”) and the Board of Directors announces the promotion of Chief Scientific Officers (CSO) Martin Juhl as a member of the Executive Management team, effective today. The appointment is a direct recognition of Martin’s significant impact on the company.

This expansion of the leadership team strengthens Cessatech's capacity to execute on its mission to develop vital new treatments for children together with its collaboration partners. Martin has proved invaluable and have been an integral part of delivering progress to date and his strategic insight and drive is an important addition to the executive management of the company. Martin Juhl is a seasoned drug-development leader with expertise spanning the entire development process. He built his foundation through 14 years at H. Lundbeck A/S and brings exceptional academic credentials: a PhD from DTU, a diploma in Pharmaceutical Medicine from Basel, three separate programs at Harvard University, and a Fulbright Scholarship at the University of Illinois.

#### **Jes Trygved, CEO, Cessatech**

I am absolutely delighted to announce Martin's promotion to the Executive Management team. This is a well-deserved step that acknowledges his great effort and large contribution during his three years with the company. Martin has been a driving force in understanding all the technical and scientific aspects, and his strategic oversight and multiple projects. His expertise and leadership will be a tremendous asset as we continue the advancement of the company."

CT001 is a nasal spray under development for treatment of acute pain in children. The development of CT001 in Europe is done in line with an endorsed paediatric investigation plan (PIP) by EMA’s Paediatric Committee. UK based company Proveca has exclusive rights to market and sell CT001 outside North American and will take the lead in the regulatory submission and later commercialization.

#### **For more information about Cessatech, please contact:**

Jes Trygved, CEO  
Phone: +45 9387 2309  
E-mail: [jes.trygved@cessatech.com](mailto:jes.trygved@cessatech.com)  
[www.cessatech.com](http://www.cessatech.com)

#### **About Cessatech**

Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.